Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Clarithromycin

FDA-approved product (tablet, oral), marketed as Biaxin, Biaxin Xl, Clarithromycin.

Registered studies
50+
Lab records
25
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Clarithromycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Chronic bronchitis
  • Duodenal ulcer
  • Infection
  • Maxillary sinusitis
  • Otitis media
  • Pharyngitis
  • Pneumonia
  • Recurrent tonsillitis
  • Sinusitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Macrolides
FDA pharmacologic class
Macrolide Antimicrobial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01FA09

Repurposing investigation

Clarithromycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA66.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli63.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae75.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis75.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 10 of 12 lab records
  • E. coli: measured active in 2 of 4 lab records
  • K. pneumoniae: measured active in 7 of 7 lab records
  • M. tuberculosis: measured active in 1 of 2 lab records
Open Clarithromycin in ChEMBL Registered studies below
Show the 25 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Clarithromycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Modified Non-clarithromycin Triple Therapy in Eradicating Helicobacter Pylori

    NCT02776371 · start 2016-09

    Registered record
    Registry ID
    NCT02776371
    Conditions
    Helicobacter Pylori Eradication Rate
    Interventions
    Modified non-clarithromycin triple therapy; Sequential therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-09
    Completion
    2018-02
    Enrolment
    301

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Eradication Rate
    InterventionModified non-clarithromycin triple therapy; Sequential therapy
    PhasePhase 4
    Registry statusCompleted

  • Clarithromycin Triple Therapy Plus Bismuth for Helicobacter Pylori First-line Treatment

    NCT02732249 · start 2016-04-01

    Registered record
    Registry ID
    NCT02732249
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Esomeprazole; Bismuth Potassium Citrate; Clarithromycin; Metronidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-04-01
    Completion
    2017-09-30
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionEsomeprazole; Bismuth Potassium Citrate; Clarithromycin; Metronidazole
    PhasePhase 4
    Registry statusCompleted

  • Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication

    NCT02557932 · start 2015-09

    Registered record
    Registry ID
    NCT02557932
    Conditions
    Helicobacter Pylori Infection; Family History of Stomach Cancer
    Interventions
    Standard triple therapy; Bismuth quadruple therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-09
    Completion
    2019-09-28
    Enrolment
    352

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection; Family History of Stomach Cancer
    InterventionStandard triple therapy; Bismuth quadruple therapy
    PhasePhase 3
    Registry statusCompleted

  • Clarithromycin in Multiple Myeloma Induction Therapy

    NCT02573935 · start 2015-01

    Registered record
    Registry ID
    NCT02573935
    Conditions
    Multiple Myeloma
    Interventions
    Clarithromycin; Placebo; VCD induction therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-01
    Completion
    2016-09
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionClarithromycin; Placebo; VCD induction therapy
    PhasePhase 2
    Registry statusTerminated

  • To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects

    NCT02807051 · start 2014-09

    Registered record
    Registry ID
    NCT02807051
    Conditions
    Drug Interaction Study
    Interventions
    Pacritinib; Clarithromycin; Pacritinib and Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-09
    Completion
    2014-10
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Interaction Study
    InterventionPacritinib; Clarithromycin; Pacritinib and Clarithromycin
    PhasePhase 1
    Registry statusCompleted

  • Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection

    NCT03124199 · start 2014-02

    Registered record
    Registry ID
    NCT03124199
    Conditions
    Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
    Interventions
    Rifaximin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-02
    Completion
    2015-06
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infection Due to Helicobacter Pylori (H. Pylori)
    InterventionRifaximin
    PhasePhase 3
    Registry statusCompleted

  • Genotypic Resistance Guided Therapy in Helicobacter Pylori Eradication

    NCT01725906 · start 2012-11

    Registered record
    Registry ID
    NCT01725906
    Conditions
    Self Efficacy
    Interventions
    empirical therapy; Genotypic resistance guided therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2012-11
    Completion
    2017-12
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSelf Efficacy
    Interventionempirical therapy; Genotypic resistance guided therapy
    PhasePhase 4
    Registry statusUnknown

  • Personalized Treatment for Refractory H Pylori Infection

    NCT02547025 · start 2012-08-01

    Registered record
    Registry ID
    NCT02547025
    Conditions
    Helicobacter Pylori Infection
    Interventions
    rabeprazole+3 antibiotics; rabeprazole+bismuth+2 antibiotics; rabeprazole+amox+tetr+levo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-08-01
    Completion
    2021-10-31
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    Interventionrabeprazole+3 antibiotics; rabeprazole+bismuth+2 antibiotics; rabeprazole+amox+tetr+levo
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori

    NCT01505127 · start 2012-01

    Registered record
    Registry ID
    NCT01505127
    Conditions
    H. Pylori Infection
    Interventions
    TAK-438; Lansoprazole; Amoxicillin; Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-01
    Completion
    2013-06
    Enrolment
    650

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionH. Pylori Infection
    InterventionTAK-438; Lansoprazole; Amoxicillin; Clarithromycin
    PhasePhase 3
    Registry statusCompleted

  • RCT: Triple vs Sequential vs Concomitant Therapy H Pylori

    NCT02092506 · start 2011-12

    Registered record
    Registry ID
    NCT02092506
    Conditions
    Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
    Interventions
    10 day triple therapy; 10 day sequential therapy; 10 day concomitant therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-12
    Completion
    2014-06
    Enrolment
    462

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infection Due to Helicobacter Pylori (H. Pylori)
    Intervention10 day triple therapy; 10 day sequential therapy; 10 day concomitant therapy
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

    NCT01454076 · start 2011-11-10

    Registered record
    Registry ID
    NCT01454076
    Conditions
    Nonhematologic Malignancies; Lymphoma
    Interventions
    Ixazomib 2.5 mg; Ixazomib 4 mg Capsule A; Ixazomib 4 mg Capsule B; Ketoconazole; Rifampin; Clarithromycin; Ixazomib 4 mg Capsule B
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-11-10
    Completion
    2016-06-16
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNonhematologic Malignancies; Lymphoma
    InterventionIxazomib 2.5 mg; Ixazomib 4 mg Capsule A; Ixazomib 4 mg Capsule B; Ketoconazole +3 more
    PhasePhase 1
    Registry statusCompleted

  • Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy

    NCT01572597 · start 2011-06

    Registered record
    Registry ID
    NCT01572597
    Conditions
    Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
    Interventions
    10RAC+acetylcystein; 10RAC+metronidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2011-06
    Completion
    2012-12
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infection Due to Helicobacter Pylori (H. Pylori)
    Intervention10RAC+acetylcystein; 10RAC+metronidazole
    PhasePhase 4
    Registry statusUnknown

  • The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study

    NCT00885417 · start 2009-04

    Registered record
    Registry ID
    NCT00885417
    Conditions
    H. Pylori Infection
    Interventions
    Cravit-based sequential therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-04
    Completion
    2010-12
    Enrolment
    142

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionH. Pylori Infection
    InterventionCravit-based sequential therapy
    PhasePhase 4
    Registry statusCompleted

  • Special Investigation of Clarith/Klaricid in Patients With Non-tuberculous Mycobacterial Pulmonary Infections

    NCT01097005 · start 2009-01

    Registered record
    Registry ID
    NCT01097005
    Conditions
    Mycobacterium Infections, Atypical
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-01
    Completion
    2014-03
    Enrolment
    466

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Infections, Atypical
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

    NCT00621504 · start 2008-01

    Registered record
    Registry ID
    NCT00621504
    Conditions
    Bacterial Pneumonia
    Interventions
    Ceftaroline fosamil for Injection; IV Ceftriaxone; Placebo; Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-01
    Completion
    2009-06
    Enrolment
    606

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Pneumonia
    InterventionCeftaroline fosamil for Injection; IV Ceftriaxone; Placebo; Clarithromycin
    PhasePhase 3
    Registry statusCompleted